Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval
Phase 1
Completed
- Conditions
- Gout and Hyperuricemia
- Interventions
- Drug: repaglinide; midazolam; SHR4640; SHR4640 placeboDrug: repaglinide; midazolam; SHR4640 placeboDrug: repaglinide; midazolam; SHR4640
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06196580
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma
Phase 1
Recruiting
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Drug: SHR2554/CHOPDrug: SHR2554/CHOEP
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06173999
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of Remimazolam Tosilate for Sedation in the Upper Gastrointestinal Endoscopy
Phase 4
Completed
- Conditions
- Sedation in the Upper Gastrointestinal Endoscopy
- Interventions
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT06169995
- Locations
- 🇨🇳
The Affiliated Hospital Of Guizhou Medical University, Guiyang, Guizhou, China
🇨🇳Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT06168929
- Locations
- 🇨🇳
Central Hospital Affilated to Shandong First Medical University, Jinan, Shandong, China
A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis
Phase 2
Not yet recruiting
- Conditions
- Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
- Interventions
- Drug: HRS -8427
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT06144060
Assessment of Gastric Emptying by SHR20004 in Healthy Subjects
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Acetaminophen/SHR20004Drug: Acetaminophen/Placebo
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT06137469
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
Phase 3
Not yet recruiting
- Conditions
- Gout With Hyperuricemia in Adults
- Interventions
- Drug: HR091506 tablets + placebo of febuxostat tablets
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 750
- Registration Number
- NCT06139393
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Phase 3
Recruiting
- Conditions
- HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 1600
- Registration Number
- NCT06126640
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
Phase 3
Recruiting
- Conditions
- Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT06122389
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Phase 3
Recruiting
- Conditions
- HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT06123494
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath